Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine
Ragonnet et al., Future Pharmacology, doi:10.3390/futurepharmacol2010007 (Dosing)
Ragonnet et al., Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of.., Future Pharmacology, doi:10.3390/futurepharmacol2010007 (Dosing)
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Comparison of two HCQ dosing regimens, showing high inter-individual variability of HCQ concentrations (as in [Ruiz]), and significantly better plasma concentrations for the dosing regimen including a loading dose.
Ragonnet et al., 19 Mar 2022, peer-reviewed, 9 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Communication Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine Gwendoline Ragonnet 1, *, Elisabeth Jouve 1 , Lionel Velly 2 , Marc Leone 3 , Gary Duclos 3 , Jeremy Bourenne 4 , Karim Harti Souab 5 , Caroline Solas 6 and Romain Guilhaumou 1 1 2 3 4 5 6 *   Citation: Ragonnet, G.; Jouve, E.; Velly, L.; Leone, M.; Duclos, G.; Bourenne, J.; Harti Souab, K.; Solas, C.; Guilhaumou, R. Drug Repositioning in Intensive Care Patients and Pharmacokinetic Variability: The Illustration of Hydroxychloroquine. Future Pharm. 2022, 2, 92–98. https://doi.org/ 10.3390/futurepharmacol2010007 Academic Editor: Fabrizio Schifano Received: 7 February 2022 Accepted: 14 March 2022 Published: 19 March 2022 Publisher’s Note: MDPI stays neutral Service de Pharmacologie Clinique et Pharmacovigilance, Institut des Neurosciences des Systèmes, Inserm UMR 11600, Aix Marseille University APHM, CEDEX 5, 13385 Marseille, France; elisabeth.jouve@ap-hm.fr (E.J.); romain.guilhaumou@ap-hm.fr (R.G.) Department of Anesthesiology and Critical Care Medicine, Timone University Hospital, Aix Marseille University APHM, 13005 Marseille, France; lionel.velly@ap-hm.fr Department of Anesthesiology and Intensive Care, Timone University Hospital, Aix Marseille University APHM, 13015 Marseille, France; marc.leone@ap-hm.fr (M.L.); gary.duclos@ap-hm.fr (G.D.) Emergency Resuscitation Department, Timone University Hospital, Aix Marseille University APHM, CEDEX 5, 13385 Marseille, France; jeremy.bourenne@ap-hm.fr Intensive Care Unit, Timone University Hospital, Aix Marseille University APHM, CEDEX 5, 13385 Marseille, France; karim.harti-souab@ap-hm.fr Unité des Virus Émergents IRD190, Inserm 1207, Laboratoire de Pharmacocinétique et Toxicologie, CEDEX 5, 13385 Marseille, France; caroline.solas@ap-hm.fr Correspondence: gwendoline.ragonnet@ap-hm.fr Abstract: During the SARS-CoV-2 pandemic, hydroxychloroquine (HCQ), was among the first drugs to be tested due to demonstrated in vitro antiviral activity against SARS-CoV-2. Pharmacokinetic variability was expected due to the frequent comorbidities and pathophysiological modifications observed in severe COVID-19 patients hospitalized in intensive care units (ICUs). The aim of this study was to describe HCQ plasmatic concentrations in ICUs and assess variability factors. A multicentric retrospective study was carried in four ICUs in Marseille from March to April 2020. There were two dosing regimens: 400 mg after a 400 mg loading dose (DR1); and 600 mg without a loading dose (DR2). HCQ concentrations were determined every 2 or 3 days. The impacts of demo-graphic, biological, and clinical covariates were investigated. The median HCQ concentration was: 0.096 mg/L on day (D) 2, 0.129 mg/L on D3 to D5, 0.140 mg/L on D6 to D10 for DR1 versus 0.116 mg/L, 0.261 mg/L, and 0.30 mg/L, respectively, for DR2. At D2, 53.9% and 46.2% of patients with DR1 and DR2, respectively, presented HCQP concentrations <0.1 µg/mL and 48.2% versus 10.7% at D3 to D5. Time post-initiation, dosing regimen, nasogastric administration, and weight showed significant association with HCQ variability. The high proportion of suboptimal HCQ concentrations can be explained by a lack of optimized dosing regimen and numerous pathophysiological changes in the COVID-19/ICU population. with regard to jurisdictional claims in published maps and institutional affil- Keywords: hydroxychloroquine;..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit